Differently, EVA1B expression was negatively correlated to sensitivity to nilotinib, tamoxifen, panobinostat, docetaxel, vinorelbine, crizotinib, ethinyl estradiol, and paclitaxel in CRC. Here, EVA1B is linked to colorectal carcinoma.